mRNA-1273

Status
Phase 3
Condition
COVID-19
Intervention Type
Intramuscular (IM) Injection
Funder Type
NIH | US Federal Agency

Drug Details

mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. 

Study Purpose

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >